High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1998 Sep 22

PMID 9743539

Citations 111

Authors

G S Ogg

P Rod Dunbar

P Romero

J L Chen

V Cerundolo

Affiliations

Soon will be listed here.

Abstract

Vitiligo is an autoimmune condition characterized by loss of epidermal melanocytes. Using tetrameric complexes of human histocompatibility leukocyte antigen (HLA) class I to identify antigen-specific T cells ex vivo, we observed high frequencies of circulating MelanA-specific, A*0201-restricted cytotoxic T lymphocytes (A2-MelanA tetramer+ CTLs) in seven of nine HLA-A*0201-positive individuals with vitiligo. Isolated A2-MelanA tetramer+ CTLs were able to lyse A*0201-matched melanoma cells in vitro and their frequency ex vivo correlated with extent of disease. In contrast, no A2-MelanA tetramer+ CTL could be identified ex vivo in all four A*0201-negative vitiligo patients or five of six A*0201-positive asymptomatic controls. Finally, we observed that the A2-MelanA tetramer+ CTLs isolated from vitiligo patients expressed high levels of the skin homing receptor, cutaneous lymphocyte-associated antigen, which was absent from the CTLs seen in the single A*0201-positive normal control. These data are consistent with a role of skin-homing autoreactive melanocyte-specific CTLs in causing the destruction of melanocytes seen in autoimmune vitiligo. Lack of homing receptors on the surface of autoreactive CTLs could be a mechanism to control peripheral tolerance in vivo.

Citing Articles

Therapeutic implications of baricitinib in mouse model of vitiligo.

Kaur H, Thakur K, Parsad D, Kumar R Arch Dermatol Res. 2025; 317(1):353.

PMID: 39918618 DOI: 10.1007/s00403-025-03879-8.

Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity.

Ezzedine K, Tannous R, Pearson T, Harris J J Clin Invest. 2025; 135(2.

PMID: 39817457 PMC: 11735104. DOI: 10.1172/JCI185785.

Skin Hypopigmentation in Hematology Disorders.

Mazzetto R, Miceli P, Sernicola A, Tartaglia J, Alaibac M Hematol Rep. 2024; 16(2):354-366.

PMID: 38921184 PMC: 11204138. DOI: 10.3390/hematolrep16020036.

Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity.

Jimenez-Andrade Y, Flesher J, Park J Hematol Oncol Clin North Am. 2024; 38(5):1011-1025.

PMID: 38866636 PMC: 11368641. DOI: 10.1016/j.hoc.2024.05.002.

Spontaneous immunological activities in the target tissue of vitiligo-prone Smyth and vitiligo-susceptible Brown lines of chicken.

Falcon D, Byrne K, Sales M, Erf G Front Immunol. 2024; 15:1386727.

PMID: 38720888 PMC: 11076693. DOI: 10.3389/fimmu.2024.1386727.

References

Hara I, Takechi Y, Houghton A . Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 1995; 182(5):1609-14. PMC: 2192219. DOI: 10.1084/jem.182.5.1609. View

Erf G, SMYTH Jr J . T cells in regenerating feathers of Smyth line chickens with vitiligo. Clin Immunol Immunopathol. 1995; 76(2):120-6. DOI: 10.1006/clin.1995.1105. View

Le Poole I, van den Wijngaard R, Westerhof W, Das P . Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996; 148(4):1219-28. PMC: 1861531. View

Naughton G, Eisinger M, Bystryn J . Antibodies to normal human melanocytes in vitiligo. J Exp Med. 1983; 158(1):246-51. PMC: 2187087. DOI: 10.1084/jem.158.1.246. View

van Elsas A, van der Burg S, van der Minne C, Borghi M, Mourer J, Melief C . Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol. 1996; 26(8):1683-9. DOI: 10.1002/eji.1830260803. View

Borges E, Pendl G, Eytner R, Steegmaier M, Zollner O, Vestweber D . The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated. J Biol Chem. 1997; 272(45):28786-92. DOI: 10.1074/jbc.272.45.28786. View

Parker K, Bednarek M, Hull L, Utz U, Cunningham B, Zweerink H . Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol. 1992; 149(11):3580-7. View

Visseren M, van Elsas A, van der Voort E, Ressing M, Kast W, Schrier P . CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol. 1995; 154(8):3991-8. View

Song Y, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N . The role of tyrosinase in autoimmune vitiligo. Lancet. 1994; 344(8929):1049-52. DOI: 10.1016/s0140-6736(94)91709-4. View

10.

Skipper J, Hendrickson R, Gulden P, Brichard V, Van Pel A, Chen Y . An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med. 1996; 183(2):527-34. PMC: 2192446. DOI: 10.1084/jem.183.2.527. View

11.

Nordlund J, Kirkwood J, Forget B, MILTON G, Albert D, LERNER A . Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983; 9(5):689-96. DOI: 10.1016/s0190-9622(83)70182-9. View

12.

Fuhlbrigge R, Kieffer J, Armerding D, Kupper T . Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 1997; 389(6654):978-81. DOI: 10.1038/40166. View

13.

Duhra P, Ilchyshyn A . Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol. 1991; 16(4):303-5. DOI: 10.1111/j.1365-2230.1991.tb00383.x. View

14.

Badri A, Todd P, Garioch J, Gudgeon J, Stewart D, Goudie R . An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol. 1993; 170(2):149-55. DOI: 10.1002/path.1711700209. View

15.

Cox A, Skipper J, Chen Y, Henderson R, Darrow T, Shabanowitz J . Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994; 264(5159):716-9. DOI: 10.1126/science.7513441. View

16.

Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4(3):328-32. DOI: 10.1038/nm0398-328. View

17.

Kawakami Y, Eliyahu S, Sakaguchi K, Robbins P, Rivoltini L, Yannelli J . Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180(1):347-52. PMC: 2191573. DOI: 10.1084/jem.180.1.347. View

18.

Valmori D, Fonteneau J, Lizana C, Gervois N, Lienard D, Rimoldi D . Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998; 160(4):1750-8. View

19.

Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B . The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993; 178(2):489-95. PMC: 2191123. DOI: 10.1084/jem.178.2.489. View

20.

Altman J, Suresh M, Sourdive D, Zajac A, Miller J, Slansky J . Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 1998; 8(2):177-87. DOI: 10.1016/s1074-7613(00)80470-7. View